Arcturus Therapeutics (NASDAQ:ARCT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Arcturus Therapeutics and VistaGen Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Arcturus Therapeutics | 2 | 5 | 4 | 0 | 2.18 |
VistaGen Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Arcturus Therapeutics presently has a consensus target price of $73.0769, indicating a potential upside of 33.74%. VistaGen Therapeutics has a consensus target price of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Arcturus Therapeutics.
Earnings and Valuation
This table compares Arcturus Therapeutics and VistaGen Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Arcturus Therapeutics | $20.79 million | 64.37 | $-25,990,000.00 | ($2.15) | -25.41 |
VistaGen Therapeutics | N/A | N/A | $-20,770,000.00 | ($0.50) | -4.82 |
VistaGen Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Arcturus Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Arcturus Therapeutics | -506.70% | -52.32% | -33.21% |
VistaGen Therapeutics | N/A | N/A | -272.12% |
Volatility & Risk
Arcturus Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
Summary
VistaGen Therapeutics beats Arcturus Therapeutics on 8 of the 12 factors compared between the two stocks.